Literature DB >> 6353623

Efficacy of ampicillin and cefoxitin in the treatment of acute pelvic inflammatory disease. A comparative study.

J A de Beer, J van den Ende, H J Odendaal.   

Abstract

Sixty patients with acute uncomplicated pelvic infection were treated with cefoxitin or ampicillin alone, the purpose being to show that a relatively cheap antimicrobial agent (ampicillin) could be used. The groups (30 patients in each) were clinically comparable (P greater than 0,01--Hotelling T-square test). In the first group 2 g ampicillin was administered intravenously on admission followed by 1 g intravenously 4-hourly, and in the second group 2 g cefoxitin was administered intravenously on admission followed by 1 g intravenously every 8 hours. A good response was obtained in both groups. On the basis of cost ampicillin would seem to be the treatment of choice in uncomplicated acute pelvic infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6353623

Source DB:  PubMed          Journal:  S Afr Med J


  5 in total

Review 1.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2013-12-11

Review 2.  Role of cephalosporins in gonorrhoea and other sexually transmitted diseases.

Authors:  I Phillips
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2008-03-10

4.  Antibiotic therapy for pelvic inflammatory disease.

Authors:  Ricardo F Savaris; Daniele G Fuhrich; Jackson Maissiat; Rui V Duarte; Jonathan Ross
Journal:  Cochrane Database Syst Rev       Date:  2020-08-20

5.  Models with environmental drivers offer a plausible mechanism for the rapid spread of infectious disease outbreaks in marine organisms.

Authors:  E A Aalto; K D Lafferty; S H Sokolow; R E Grewelle; T Ben-Horin; C A Boch; P T Raimondi; S J Bograd; E L Hazen; M G Jacox; F Micheli; G A De Leo
Journal:  Sci Rep       Date:  2020-04-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.